TRANSACTIONS OF THE INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGIES
Institute of Molecular Biology, Ministry of Science and Education of the Republic of Azerbaijan
TRANSACTIONS OF THE INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGIES
Institute of Molecular Biology, Ministry of Science and Education of the Republic of Azerbaijan
Institute of Molecular Biology, Ministry of Science and Education of the Republic of Azerbaijan, 11 Izzat Nabiyev Str., AZ1073, Baku, Azerbaijan
*For correspondence: tmammedov@gmail.com
Tarlan Mamedov: https://orcid.org/0000-0002-5747-4990
The continuous emergence of SARS-CoV-2 variants of concern has highlighted important limitations of first-generation COVID-19 vaccines developed against the ancestral Wuhan spike protein. Although these vaccines provided strong protection against severe disease and mortality, the accumulation of mutations in the spike protein, particularly within the receptor-binding domain (RBD), progressively reduced their ability to prevent infection and facilitated immune escape. In contrast, vaccine approaches that combine multiple complementary viral antigens have shown greater potential to maintain broad protective immunity despite ongoing viral evolution and immune escape. In this article, we discuss the scientific basis of a plant-produced recombinant COVID-19 cocktail vaccine that demonstrated sustained immunogenicity and cross-variant effectiveness despite being designed from the ancestral Wuhan SARS-CoV-2 sequence. Based on our experimental studies, we propose that this broad protective potential results from the integration of three key design elements: (i) targeting conserved and functionally constrained epitopes within the RBD, (ii) combining RBD and nucleocapsid (N) proteins in a multi-antigen vaccine formulation, and (iii) applying glycoengineering strategies to optimize antigen structure and immune recognition, thereby broadening the immune response and reducing susceptibility to viral immune escape. We further discuss the advantages of plant molecular farming, particularly transient expression in Nicotiana benthamiana, as a rapid, scalable, and cost-effective platform for recombinant vaccine production. Our studies demonstrated that plant-produced glycosylated and deglycosylated RBD antigens retain functional receptor-binding activity and induce strong neutralizing antibody responses. Moreover, when combined with the N protein, these antigens maintained effectiveness against highly divergent SARS-CoV-2 variants, including Omicron. Importantly, the principles underlying this vaccine design may extend beyond COVID-19. The strategic combination of conserved and immunologically complementary antigens provides a rational framework for the development of broadly protective vaccines against future pandemic threats and other rapidly evolving emerging pathogens. In particular, our findings suggest that integrating conserved and immunologically complementary antigens may represent a universal vaccine design strategy to combat future pandemics caused by rapidly evolving pathogens.
---
This article is a review study based exclusively on previously published literature and does not involve human participants, animals, or the collection of primary data. Therefore, ethical approval and informed consent were not required.
No specific funding was received for the preparation of this review article. However, the scientific background, technological developments, and vaccine design concepts discussed in this review were developed through research projects awarded to Tarlan Mamedov and supported by TÜBİTAK (Project Nos. 114Z258, 114Z863, 115S077, 218S723 and
The author declares no conflict of interest.
Baden L.R., El Sahly H.M., Essink B. et al. (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl J. Med., 384: 403–416; doi:10.1056/NEJMoa2035389.
Bally J., Jung H., Mortimer C. et al. (2018) The rise and rise of Nicotiana benthamiana: A plant for all reasons. Annu. Rev. Phytopathol., 56: 405–426.
Barda N., Dagan N., Balicer R.D. (2021) BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med., 384(20): 1970.
Benvenuto E., Broer I., D’Aoust M.A., Hitzeroth I., Hundleby H., Menassa R., Oksman-Caldentey K.M. et al. (2023) Plant molecular farming in the wake of the closure of Medicago Inc. Nature Biotechnology, 41: 893–894.
Bouillon K., Baricault B., Botton J., Jabagi M.J., Bertrand M., Semenzato L., Vu S.L., Drouin J. et al. (2022) Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe COVID-19 outcomes. BMJ Med., 1(1): e000104.
Cao Y., Wang J., Jian F., Xiao T., Song W., Yisimayi A., Huang W. et al. (2022) Omicron escapes the majority of existing neutralizing antibodies. Nature, 602: 657–663.
Chen Q., Lai H. (2015) Gene delivery into plant cells for recombinant protein production. BioMed Research International, 2015: 932161.
Dagan N., Barda N., Kepten E., Miron O., Perchik O., Katz M.A., Hernán M.A. et al. (2021) BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med., 384(15): 1412–1423.
Farrance C.E., Chichester J.A., Musiychuk K. et al. (2011) Antibodies to plant-produced Plasmodium falciparum protein Pfs25 exhibit transmission-blocking activity. Hum. Vaccin., 7(sup1): 191–198.
Gleba Y., Klimyuk V., Marillonnet S. (2007) Viral vectors for the expression of proteins in plants. Curr. Opin. Biotechnol., 18: 134–141.
Goulet M.C., Gaudreau L., Gagné M. et al. (2019) Production of biopharmaceuticals in Nicotiana benthamiana. Front. Plant Sci., 10: 735.
Gun N., Mamedov T. (2022) Flexible approaches for production of recombinant proteins in plants. Med Science, 11: 1.
Harvey W.T. et al. (2021) SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol., 19: 409–424.
He X., Hong W., Pan X., Lu G., Wei X. (2021) SARS-CoV-2 Omicron variant: Characteristics and prevention. Med. Comm., 2(4): 838–845.
Klimyuk V., Pogue G., Herz S., Butler J., Haydon H. (2014) Production of recombinant antigens in Nicotiana benthamiana using magnifection technology. Curr. Top. Microbiol. Immunol., 375: 127–154.
Křenek P., Šamajová O., Luptovčiak I., Doskočilová A., Komis G., Šamaj J. (2015) Transient plant transformation via Agrobacterium tumefaciens. Biotechnol. Adv., 33: 1024–1042.
Logunov D.Y. et al. (2021) Safety and immunogenicity of rAd26 and rAd5 COVID-19 vaccine. Lancet, 396: 887–897.
Mamedov T., Ghosh A., Jones M. et al. (2012) Production of non-glycosylated recombinant proteins in Nicotiana benthamiana. Plant Biotechnol. J., 10: 773–782.
Mamedov T., Chichester J.A., Jones R.M. et al. (2016) Production of protective antigen from Bacillus anthracis in plants. PLoS One, 11(4): e0153956.
Mamedov T., Cicek K., Gulec B. et al. (2017) Production of recombinant proteins via Endo H co-expression. PLoS One, 12(8): e0183589.
Liu L., Wang P., Nair M.S. et al. (2020) Potent neutralizing antibodies against SARS-CoV-2 spike. Nature, 584: 450–456.
Polack F.P., Thomas S.J., Kitchin N. et al. (2020) Safety and efficacy of BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med., 383: 2603–2615.
Pillet S., Arunachalam P.S., Andreani G. et al. (2022) Plant-derived virus-like particle vaccine for COVID-19. Cell Mol. Immunol., 19: 222–233.
Ramasamy M.N., Minassian A.M., Ewer K.J. et al. (2020) Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine. Lancet, 396: 1979–1993.
Royal J.M., Simpson C.A., McCormick A.A. et al. (2021) Plant-based SARS-CoV-2 vaccine candidate. Vaccines, 9: 1347.
Rybicki E.P. (2010) Plant-made vaccines for humans and animals. Plant Biotechnol. J., 8: 620–637.
Ruocco V., Strasser R. (2022) Expression of SARS-CoV-2 antigens in Nicotiana benthamiana. Plants, 11: 1093.
Walls A.C. et al. (2020) Structure and antigenicity of SARS-CoV-2 spike glycoprotein. Cell, 181: 281–292.
Ward B.J. et al. (2021) Plant-derived virus-like particle vaccine trial. Nature Medicine, 27: 1071–1078.
Yuan M. et al. (2020) Structural basis of antibody responses to SARS-CoV-2. Science, 369: 1119–1123.
Yuksel D., Yusifova G., Hasanova A.S., Mammedov T. (2025) Enhancing recombinant protein production in Nicotiana benthamiana. European Journal of Biology, 4: 4.
Received: April 19, 2026; Reviewed: May 26, 2026; Accepted: June 5, 2026
DOI:
https://doi.org/10.62088/timbb/10.1.7Keywords:
SARS-CoV-2, COVID-19 vaccine, receptor-binding domain, glycoengineering, nucleocapsid protein, plant molecular farming, Nicotiana benthamiana, cross-variant immunity, Omicron, vaccine design
Mamedov T. (2026). A rationally designed Wuhan-sequence-based COVID-19 vaccine that maintained effectiveness against diverse SARS-CoV-2 variants, including Omicron: What was the key to success?. TIMBB, 10 (1), 62-71.